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Abstract
Objective: To examine the generalizability of two National Institutes of Health (NIH)-funded
double-blind randomized placebo-controlled clinical trials in patients with chronic Lyme disease
and to determine whether selection factors resulted in the unfavorable outcomes.
Design: Epidemiologic review of the generalizability of two trials conducted by Klempner et al.
This paper considers whether the study group was representative of the general chronic Lyme
disease population.
Results: In their article in The New England Journal of Medicine, Klempner et al. failed to discuss the
limitations of their clinical trials. This epidemiologic review argues that their results are not
generalizable to the overall Lyme disease population. The treatment failure reported by the authors
may be the result of enrolling patients who remained ill after an average of 4.7 years and an average
of 3 previous courses of treatment. The poor outcome cited in these trials may be explained by
having selected patients who had undergone delayed treatment or multiple treatments
unsuccessfully. These selection factors were not addressed by the studies' authors, nor have they
been discussed by reviewers. The trials have been over-interpreted by the NIH and widely
publicized in a press release. The results have been extrapolated to other groups of Lyme disease
patients by commentators, by a case discussant in an influential medical journal, and by health
insurance companies to deny antibiotic treatment.
Conclusion: The Klempner et al. trials are assumed to be internally valid based on a Randomized
Control Trial (RCT) design. However, this review argues that the trials have limited generalizability
beyond the select group of patients with characteristics like those in the trial. Applying the findings
to target populations with characteristics that differ from those included in these trials is
inappropriate and may limit options for chronic Lyme disease patients who might benefit from
antibiotic treatment.
Background
According to the Centers for Disease Control and Preven-
tion (CDC), Lyme disease is the fastest growing vector-
borne disease in the United States with over 40,000 cases
reported during 2001–2002, representing a 40% annual
increase in incidence [1]. Studies from the 1990's suggest
that the actual number of cases may be as much as twelve
times higher when factoring in underreporting [1].
Enzootic cycles of Lyme disease can be maintained in a
wide range of ecologic conditions [2,3]. Forty-nine of 50
states and the District of Columbia in the USA had
reported Lyme disease cases by 1998 [4] The areas of the
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country endemic for Lyme disease have expanded [5]. In
New York, over an 11 year period, cases have spread
throughout the state from the original southeastern focus
[6]. Increasing numbers have also been reported in the
United Kingdom, France, and Sweden [3].
Lyme disease presents formidable challenges because of
the high percentage of cases that become chronic in the
absence of early treatment [7,8] and the complexity and
cost of managing the long-term use of antibiotics in treat-
ing chronic disease [9]. The number of Lyme disease cases
that become chronic has been reported to be as low as
0.5% to 13% per year for patients treated at the time of an
erythema migrans rash [10-13]. However, as many as 34%
to 62% developed the chronic form of the disease in two
studies [7,8]. A third of Lyme disease patients in one pop-
ulation-based retrospective cohort treated in the late
1980's were found to have chronic Lyme disease an aver-
age of 6.2 years after treatment [7]. Two thirds of 215
Lyme disease patients diagnosed in Westchester County,
New York, USA remained ill an average of 3.2 years after
treatment [8].
Analysis
The Klempner et al. trials that appeared in the New Eng-
land Journal of Medicine examined the benefits of treating
chronic Lyme disease patients with one month of intrave-
nous ceftriaxone followed by eight weeks of oral doxycy-
cline [14]. Chronic Lyme disease patients who received
antibiotics for 90 days were no more likely to improve
than those receiving placebo. The high treatment failure
rate of 60% was significantly greater than the 0–37% fail-
ure rates documented in previous studies of chronic Lyme
disease [15-20] (Table 1). For this reason, it seemed pru-
dent to examine the validity of the authors' conclusions
regarding the treatment, in general, of chronic Lyme dis-
ease patients.
Internal validity of the Lyme disease trials conducted by 
Klempner et al
Blinded, randomized controlled trials (RCT) are seen as
the most reliable evidence in medicine if internal and
external validity can be assumed [21,22]. Klempner et al.
enrolled a homogeneous patient population, used a rand-
omized design, standardized treatment, placebo-controls,
blinding, a validated quality of life outcome measure, and
intent-to-treat analysis. The study suggested that treat-
ment for 3 months was no better than placebo for a select
population who remained ill an average of 4.7 years after
an average of more than three courses of treatment [14].
Assessing the internal validity of these trials for estimating
efficacy in the study population is beyond the scope of
this paper; for present purposes, results of the trials are
assumed to be internally valid, based on the RCT design.
However, achieving internal validity does not imply gen-
eralizability.
Generalizability of the Lyme disease trials conducted by 
Klempner et al
Generalizability can be assessed by considering factors
that may influence the outcome of an intervention across
varied medical settings with diverse patient populations
[23]. The authors of the trials did not discuss generaliza-
bility to the everyday medical setting.
Investigators of other conditions have demonstrated the
consequences when a study fails to address the broader
group seen in everyday clinical practice. Jüni et al. cites the
lack of effectiveness of fibrinolytic therapy for suspected
acute myocardial infection when generalizing the results
from a younger group to the elderly and when generaliz-
ing timely fibrinolytic therapy to patients presenting more
than 12 hours after symptom onset [22].
This review examines whether the Lyme disease patients
enrolled in the Klempner et al. trials represent those com-
monly seen in everyday practice. Subjects were eligible if
they were at least 18 years old, had a history of Lyme dis-
ease acquired in the United States, and had at least one of
the following: a history of a single or multiple erythema
skin lesion, early neurologic or cardiac symptoms attrib-
uted to Lyme disease, radiculoneuropathy, or Lyme arthri-
tis. Documentation by a physician of previous treatment
of acute Lyme disease with a recommended antibiotic reg-
imen was also required. At the time of enrollment, all
patients had one or more of the following symptoms that
interfered with their function: widespread musculoskele-
tal pain, cognitive impairment, radicular pain, paresthe-
sias, or dysesthesias. Profound fatigue often accompanied
one of these symptoms. The chronic symptoms had to
have begun within 6 months after the initial infection
with B. burgdorferi and had to have persisted for at least 6
months but less than 12 years.
Patients were excluded if they had hypersensitivity to the
study medication, had previously received parenteral anti-
biotic therapy for 60 days or more for their current symp-
toms, had active inflammatory synovitis, had a coexisting
condition that could have accounted for their symptoms,
or were unable to discontinue medication that could
interfere with the evaluation of their response to the treat-
ment regimen (e.g., narcotic analgesics or prednisone in a
dose of 10 mg per day or more). Patients with a positive
polymerase-chain-reaction (PCR) test for B. burgdorferi
DNA in plasma or cerebrospinal fluid at baseline were
also excluded.
The results of the trials are not generalizable to patients
receiving treatment for chronic Lyme disease within 6Epidemiologic Perspectives & Innovations 2006, 3:12 http://www.epi-perspectives.com/content/3/1/12
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months of their initial presentation, because the investiga-
tors excluded these patients from study. Chronic Lyme
disease has been reported as early as 2–4 weeks after onset
of acute disease [18,24]. The impact of treatment delay is
poorly understood. Asch et al. describe a retrospective
cohort of 215 subjects with an average 6-week delay in
getting treatment [8]. Sixty-two percent were ill an average
of 3.2 years after initial treatment. The Klempner study did
not consider the impact of treatment delay on long-term
treatment failure. In the published report, the authors did
not make it very clear that participants had already been
ill with Lyme disease an average of 4.7 years at the time of
their enrollment in the study [14]. Information about this
potential selection factor is found only in the tables –
rather than in the results section or the abstract, where it
should have been in order to avoid misinterpretation of
the results [14]. The Klempner report's failure to take aver-
age duration of study participants' illness into account
when interpreting the results gives readers the potentially
misleading impression that the Klempner et al. study can
Table 1: Diversity of chronic Lyme disease studies: populations, treatments, durations and outcomes.
Study Year Size Patient 
population
Type of study Treatment Duration of 
Rx (days)
Outcome
Dattwyler [20] 1988 23 Late Lyme disease in 
the NorthEast (NE) 
USA
Randomized trial IV Ceftriaxone vs IV 
penicillin
14 vs 10 92% responded to ceftriaxone, 
50% improved with penicillin
Logigian [15] 1990 27 Neurologic LD 
patients in NE USA
Case series IV Ceftriaxone 14 63% improved, 22% improved 
but then relapsed, and 15% had 
no change in their condition
Hassler [19] 1990 135 Stage three 
borreliosis 
manifestations of at 
least six months' 
duration in Germany
Randomized trial IV Cefotaxime vs IV 
penicillin G
10 87.9% vs 61.3% respectively Full 
or incomplete remission of 
symptoms in.
Wahlberg [17] 1994 100 Consecutive LD 
patients in Finland
Case series IV Ceftriaxone, oral 
amoxicillin plus 
probenecid and/or 
oral cefhadroxil.*
14 to114 31% of 13 treatments successful 
with 14 days of IV ceftriaxone 
alone, 89% of 56 treatments 
with IV ceftriaxone followed by 
100 days of amoxycillin plus 
probenecid successful, and 83% 
of 23 treatments with 
ceftriaxone followed by 100 
days of cephadroxil successful.
Donta [18] 1997 277 Chronic LD in NE 
USA
Case series Oral tetracycline 30 to 330 20% of the patients were cured; 
70% of the patients' conditions 
improved.
Logigian [16] 1999 18 Neurologic LD in 
NE USA
Case series IV ceftriaxone 28 100% of 18 patients rated 
themselves as back to normal or 
improved.
Klempner [14] 2001 107 LD with persistent 
symptoms in NE 
USA
Randomized trial IV ceftriaxone + 
oral doxycycline
90 40% vs 36% for treatment vs 
placebo in improvement in 
quality of life (SF-36)
Krupp [46] 2003 55 LD with disabling 
fatigue in NE USA
Randomized trial IV ceftriaxone 30 69% rx vs 23% for treatment vs 
placebo in the primary outcome 
– fatigue. No improvement on 
cognitive function or the 
clearance of Borrelia OspA 
antigen in the spinal fluid
Donta [25] 2003 235 LD with fatigue, 
musculoskeletal 
pain, and 
neurocognitive 
dysfunction in NE 
USA
Case series Oral macrolide + 
hydroxychloroquine
90 80% had self reported 
improvements of 50% or more
Dattwyler [27] 2005 201 Late LD in NE USA Randomized trial IV ceftriaxone 14 vs. 28 76% vs 70% clinical cure rates 
for 14 and 28 days respectively
Borg [26] 2005 65 Neurologic LD in 
Sweden
Randomized trial IV ceftriaxone vs 
oral doxycycline
10 to 14 79% vs 72% completely 
recovered, the remaining 
improved.
* Patients treated with different combinations of oral, IM or IV antibiotics and variable durations of treatment.Epidemiologic Perspectives & Innovations 2006, 3:12 http://www.epi-perspectives.com/content/3/1/12
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be generalized to the overall population of patients that
present with persistent symptoms and a history of Lyme
disease.
Furthermore, the results of the trials may not be generaliz-
able to chronic Lyme disease patients presenting for a first
or second retreatment. The authors did not discuss the sig-
nificance of the study participants' average of 3 previous
courses of antibiotics [14]. Again, this potential selection
factor is only described in the tables, rather than, more
appropriately, in the results section or the abstract [14].
Initial retreatment is both commonplace and successful in
previous studies [15-20,25-27]. By failing to enroll a suffi-
cient number of patients who had received fewer than
three previous courses of treatment, the researchers may
have excluded the subset of Lyme disease patients most
likely to benefit from retreatment.
The investigators can only draw conclusions about the 3-
month combination of oral and intravenous antibiotic
treatment that was chosen for the study and not about
longer treatments or simultaneous administration of mul-
tiple antibiotics. They dismissed the potential benefit of
longer treatment or other combinations of antibiotics by
saying "Experience with other chronic infectious diseases
caused by persistent bacteria (e.g., syphilis, tuberculosis,
and helicobacter infection) suggests that it is unlikely that
more prolonged antibiotic therapy or a different combi-
nation of antibiotics would result in greater improvement
than was observed in this study" [[14], p.89]. The authors
did not provide references to support this statement; pro-
longed antibiotic use or simultaneous administration of
multiple antibiotics have been effective for tuberculosis
[28] and helicobacter infection [29].
The two trials cannot be generalized to chronic Lyme dis-
ease patients who have never received treatment, since
these patients were excluded from study. Up to one third
of patients never present with the classic erythema
migrans rash, Bell's palsy, meningitis, heart block, and/or
arthritis, which are indications of early Lyme disease
[17,18,20,27]. It is not clear that the same treatment that
is effective for early Lyme will be equally effective for
untreated chronic Lyme. Prolonged antibiotic treatment
may be called for in cases of untreated chronic Lyme.
The authors did not discuss the reasons two Klempner et
al. trials failed whereas previous studies showed a benefit
of retreatment with antibiotics [15-20]. Wells stressed the
need for authors of clinical trials to keep informed about
the results of other relevant studies [30]. There were six
previous studies of chronic Lyme disease that described
differing treatment regimens and durations, and broader
populations than those included in the Klempner et al. tri-
als (Table 1). Both oral and intravenous antibiotics were
effective for late, chronic, neurologic, and stage 3 Lyme
disease in Europe and the USA. The treatment duration
ranged from 10 to 330 days. Given the narrowly defined
study population in the Klempner et al. trials, the results
of previous treatment studies should not be ignored when
drawing general conclusions about effects in a broader tar-
get population.
Misinterpretation of the results
On June 12, 2001 the National Institutes of Health (NIH)
issued a press release titled "Chronic Lyme Disease Symp-
toms Not Helped by Intensive Antibiotic Treatment." The
release quotes Klempner as follows, "We think it is
unlikely that a longer course of treatment or different anti-
biotic combination would result in greater improvement
than what we found in these studies" [[31], p.1]. The state-
ment did not discuss the limited generalizability of the
Klempner study [31].
Subsequent reviews of the trials have discouraged treat-
ment for chronic Lyme disease without addressing their
limitations. A 2002 review in Arthritis Research cited these
trials as evidence that "Prolonged antibiotic treatment for
suspected 'chronic Lyme disease syndrome' is therefore
expensive, ineffective, burdened with side effects and
should be avoided" [[32], p.23]. Blacklow, in a summary
and comment in the Journal Watch Infectious Diseases,
stated "it is unlikely that tinkering with antibiotic choices
and durations of therapy will alter these findings" [[33],
p.1]. This conclusion restates Klempner et al.'s dismissal
of the value of additional antibiotic therapy or a different
combination of antibiotics and even expands upon it in
ways that were not suggested by the studies' results.
Several authors of other studies inappropriately cite the
Klempner et al. trials to conclude that chronic Lyme dis-
ease is not infectious. Authors of a recently completed
clinical trial on early Lyme disease [13] note that "There is
no scientific evidence to justify prolonged antibiotic ther-
apy for patients with any manifestation of Lyme disease,
and our study and that of others [34] should further help
to discourage such practice. In addition, antibiotics are no
better than placebo in treating patients who carry the label
of 'chronic Lyme disease,' probably because evidence indi-
cates that this entity is not infectious" [[35], p.577]. The
authors make this statement without citing evidence that
supports the notion that chronic Lyme disease is not
infectious, other than the Klempner trials.
In another published paper citing the Klempner et al. tri-
als as evidence that post-Lyme syndrome is distinct from
Lyme disease, patients were said to have "developed a syn-
drome of diffuse arthralgia, myalgia, fatigue, and subjec-
tive cognitive difficulty during or soon after LD" [[36],
p.385]. However, these so-called "post-Lyme" symptomsEpidemiologic Perspectives & Innovations 2006, 3:12 http://www.epi-perspectives.com/content/3/1/12
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are also typical of Lyme disease itself. The authors did not
present clear evidence that "post-Lyme syndrome" was a
distinct illness in patients who are demonstrably no
longer infected with Lyme spirochetes.
Another author inappropriately cites the two Klempner et
al. trials to support a position that Lyme disease is neither
infective nor inflammatory. In an editorial commentary in
the Journal of Infectious Diseases, Radolf considered the two
trials pivotal in supporting the position that "the majority
of physicians and scientists, the so-called mainstream
camp, maintain that PTCLD (post-treatment chronic
Lyme disease) is neither infectious nor inflammatory in
nature" [[37], p.948], and that "researchers have failed to
garner convincing and reproducible evidence for either
persistent infection or ongoing inflammation" [[37],
p.948]. Radolf cites a second Klempner et al. paper [38]
derived from the same two clinical trials, stating there was
no evidence of persistent or viable infection by numerous
measures including cultures and PCR, CSF pleocytosis,
elevated white blood count, or increased erythrocyte sed-
imentation rate. Neither Radolf [37] nor Klempner et al.
[38] discussed the poor sensitivities of these tests for
chronic Lyme disease [15]. For example, only one of a
series of twenty-seven cases of neurologic Lyme disease
presented with a CSF pleocytosis and that case had only 7
cells [15]. Furthermore, PCR and culture tests may only be
useful for subjects with early Lyme disease who have never
been treated with antibiotics [39]. Neither increased white
blood count nor erythrocyte sedimentation rate is ele-
vated in acute or chronic Lyme disease [40].
A discussant in a clinician's corner published in JAMA
[41] cited the Klempner et al. trials when advising against
treatment of a 58-year-old man with chronic Lyme dis-
ease. The man, who lived in the Lyme endemic area of
Martha's Vineyard, had been ill for 10 years. This man had
a history of Bell's Palsy and in August 1992, "he became
less competent mentally. He could not do simple math
and he became depressed. In 1994, he was diagnosed as
having Lyme disease. At that time, he complained of neck
pain radiating to his left shoulder and hand; numbness
and tingling in his hand; back pain that radiated down his
left leg; bilateral joint aches in both elbows and, to a lesser
extent, his shoulders; bilateral tinnitus; and periodic
blurred vision" [[41], p.1002]. The man was treated with
prednisone in 1992. Antibiotic treatment was delayed
until 1994. The symptoms improved with repeated
courses of oral tetracycline and clarithromycin, only to
recur. The discussant cited the Klempner et al. trials as evi-
dence against the value of further antibiotic treatment.
Instead, he advised treatment for fibromyalgia even
though he admitted that the patient did not meet the cri-
teria for this condition. Fibromyalgia treatment has been
disappointing for people with this kind of history [42].
Finally, two health insurance companies cite the Klemp-
ner et al. trials as justification for not covering treatment
with intravenous antibiotics. One company policy states
that they "will not cover IV therapy beyond 28 days for
Lyme Disease without review and input from a trained
Infectious Disease Specialist approved by GHI-HMO."
Furthermore, the company "will not cover IV therapy for
Lyme Disease for Chronic Lyme Disease or Post-Lyme
Disease Syndrome without input from a trained Infec-
tious Disease Specialist approved by GHI-HMO " [43].
Citing the Klempner et al. trials, [44] Cigna does not cover
any treatment for patients with persistent symptoms and
a history of Lyme disease, unless recurrent arthritis, cen-
tral nervous system (CNS), or peripheral nervous system
involvement can be demonstrated. Treatment for chronic
Lyme disease would otherwise be considered experimen-
tal, investigational, or unproven and therefore not cov-
ered, resulting in limited treatment options for many
patients who might have benefited from additional anti-
biotics.
Conclusion
Klempner et al. did not adequately critique the generaliz-
ability of their trials. This review argues that the study par-
ticipants were not representative of the overall population
of chronic Lyme disease patients that present with persist-
ent symptoms and a history of disease. Limited generaliz-
ability has been a problem of other randomized trials [21]
and it remains one here.
This review argues that the poor treatment response in the
Klempner et al. trials may be explained by having selected
patients who had undergone delayed treatment or multi-
ple treatments unsuccessfully. The quality of life of sub-
jects enrolling in the Klempner et al. trials was worse than
that of the average type II diabetic or patient recovering
from a heart attack, and as poor as that of subjects suffer-
ing from congestive heart failure [14]. In other words, it
may be an example of offering patients "too little too
late."
Klempner himself described his concerns about the study
population to the editors of Science: "After a year of adver-
tising, only 57 subjects had been enrolled. The goal is to
get 260 by the time the study ends in 2 years. More than
1200 people have expressed interest, and 700 have come
in for screening. But only 1 in 10 who appear in the clinic
fits the study's strict criteria" [45, p.1431]. Neither in the
Science  interview [45], nor when reporting the trials'
results in the New England Journal of Medicine [14], did
Klempner discuss whether the strict criteria was a factor
leading to the average 4.7 year onset of illness of subjects
enrolled.Epidemiologic Perspectives & Innovations 2006, 3:12 http://www.epi-perspectives.com/content/3/1/12
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Two additional randomized trials and one case series have
been published since the 2001 Klempner et al. trials [25-
27]. A fourth trial by Krupp supported antibiotic treat-
ment for a subset of chronic Lyme disease patients with
fatigue [46]. One month of intravenous ceftriaxone was
effective at reducing the primary fatigue endpoint but not
the secondary endpoints of cognitive function or OspA
antigen [46]. These additional trials of chronic Lyme dis-
ease [25, 26, 27, 46] continue to suggest that treatment
may be beneficial for some subgroups of patients who
were not well represented in the Klempner et al. trials.
In summary, this review exposes the limited generalizabil-
ity of the findings of Klempner et al., and the overreaching
impact these trials have had on influencing policies that
affect unrepresented patient groups. In interpreting the
results of these trials, physicians should consider the select
group of patients that were chosen for study and whether
the patients in their care might respond differently to
treatment.
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